Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Dodeclonium→

Dodeclonium Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
123247-90-5
Molecular formula
C22H39ClNO+
Molecular weight
369 g/mol
Drug class
Quaternary ammonium antisepticlocal cationic anti-infective agent
Mechanism of action
Dodeclonium is the cationic antiseptic moiety of dodeclonium bromide. Its long-chain quaternary ammonium structure is consistent with local membrane-active antiseptic activity; the exact mechanism and activity depend on the formulated salt and product.
Indications / reported uses
  • Used in selected topical combination preparations for local antiseptic care of painful anal or haemorrhoidal conditions, where authorised. The marketed product and salt form determine the clinical use.

Sources: https://www.ebi.ac.uk/chebi/CHEBI%3A135977 · https://pubchem.ncbi.nlm.nih.gov/#query=dodeclonium · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Dodeclonium Environmental Risk Assessment (ERA) (the Dodeclonium ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.